BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price gapped up prior to trading on Friday . The stock had previously closed at $8.05, but opened at $8.49. BioCryst Pharmaceuticals shares last traded at $7.97, with a volume of 798,615 shares.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BCRX. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Stock Performance

The business’s 50-day moving average price is $7.60 and its 200-day moving average price is $7.56. The stock has a market cap of $1.61 billion, a P/E ratio of -12.77 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. The company’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period last year, the business posted ($0.19) earnings per share. As a group, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently modified their holdings of BCRX. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. DRW Securities LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth $74,000. Xponance Inc. grew its holdings in BioCryst Pharmaceuticals by 13.1% during the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 1,505 shares during the period. Quantinno Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $82,000. Finally, SkyView Investment Advisors LLC lifted its position in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.